Repligen Corp
NASDAQ:RGEN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
119.79
208.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Repligen Corp
Repligen Corp
Interest Income Expense
Repligen Corp
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Repligen Corp
NASDAQ:RGEN
|
Interest Income Expense
$12.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
41%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Interest Income Expense
-$310m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
Danaher Corp
NYSE:DHR
|
Interest Income Expense
-$179m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-122%
|
CAGR 10-Years
-5%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Interest Income Expense
-$76.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-12%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Interest Income Expense
-$29m
|
CAGR 3-Years
28%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Interest Income Expense
-$632m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-21%
|
|
Repligen Corp
Glance View
Repligen Corp., a prominent player in the bioprocessing industry, has carved out a niche that centers on providing high-quality bioprocessing solutions for the production of biologics, particularly therapeutic proteins and monoclonal antibodies. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen has transformed itself from a developer of research tools into a critical partner for biopharmaceutical manufacturers. The company is primarily engaged in producing innovative products that enhance the efficiency and effectiveness of biomanufacturing processes. Its offerings range from filtration systems to cell culture media, all designed to accelerate drug development and ensure consistent product quality. Through strategic acquisitions and partnerships, Repligen has expanded its portfolio and technological capabilities, positioning itself as a leading provider in a high-demand market driven by the growing need for biologic therapies. For investors, Repligen represents a compelling opportunity rooted in its impressive growth trajectory and strong financial performance. The company has consistently reported rising revenues, bolstered by the increasing global demand for biologics and bioprocessing innovations. Repligen’s continuous investment in research and development ensures that it remains at the forefront of technological advancements, while its robust customer base includes some of the world’s leading pharmaceutical and biotech companies. With a strong balance sheet and a commitment to operational excellence, Repligen is poised for sustainable growth in an industry that is expected to expand significantly over the coming years. For those seeking exposure to the booming biopharmaceutical sector, Repligen offers a unique position that balances innovation, growth potential, and strategic leadership.
See Also
What is Repligen Corp's Interest Income Expense?
Interest Income Expense
12.6m
USD
Based on the financial report for Sep 30, 2024, Repligen Corp's Interest Income Expense amounts to 12.6m USD.
What is Repligen Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
41%
Over the last year, the Interest Income Expense growth was -40%.
You don't have any saved screeners yet
